Fat and the liver - A molecular overview

Seminars in Gastrointestinal Disease

Volumn 13, Issue 1, 2002, Pages 3-16

  Harrison, Stephen A ^a   Diehl, Anna Mae ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; INSULIN; LIVER ENZYME;

ADAPTATION; AGED; ARTICLE; CASE REPORT; CHRONIC DISEASE; CHRONIC HEPATITIS; CHRONIC INFLAMMATION; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; FATTY ACID METABOLISM; FATTY LIVER; FEMALE; HUMAN; INSULIN RESISTANCE; LIVER CIRRHOSIS; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER DISEASE; OBESITY; OXIDATIVE STRESS; SYMPTOM;

CHRONIC DISEASE; FATTY LIVER; HUMANS;

EID: 0036211591     PISSN: 10495118     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (112)

1. Nonalcoholic steatohepatis: Mayo clinic experiences with a hitherto unnamed disease
2. Nonalcoholic steatohepatitis
3. Nonalcoholic steatohepatitis
4. Nonalcoholic steatohepatitis
5. Nonalcoholic steatohepatitis
6. Prevalence of fatty liver in a general population of Okinawa, Japan
7. "Silent" nonalcoholic steatohepatitis can be mild or aggressive
8. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors
9. Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic patients
10. Syndrome X: 10 Years after
11. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease
12. Association of nonalcoholic fatty liver disease with insulin resistance
13. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities
14. Nonalcoholic steatohepatitis: An expanded clinical entity
15. Steatohepatitis in obese children: A cause of chronic liver dysfunction
16. Idiopathic steatohepatitis in childhood: A multicenter retrospective study
17. Nonalcoholic steatohepatitis: A study of 39 patients
18. The natural history of nonalcoholic steatohepatitis: A follow-up study study of forty-two patients for up to 21 years
19. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity
20. Alcohol like liver disease in nonalcoholics. A clinical and histologic comparison with alcohol induced liver injury
21. Markers of chronic alcohol ingestion in nonalcoholic steatohepatitis: An aid to diagnosis
22. Nonalcoholic fatty liver disease: A spectrum of clinical and pathologic severity
23. Liver fibrosis in overweight patients
24. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
25. Ninety patients with non-alcoholic steatohepatitis: Insulin resistance, familial tendency, and severity of disease
26. The ratio of aspartate aminotransferase to alanine aminotransferase: Potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease
27. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis
28. Recurrance of nonalcoholic steatohepatitis following liver transplantation
29. NAFLD and NASH: Important diseases before and after liver transplantation
30. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease
31. Development of nonalcoholic fatty liver disease after orthotopic liver transplant for cryptogenic cirrhosis
32. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease
33. Steatohepatitis: A tale of two "hits"?
34. Tissue-specific over-expression of lipoprotein lipase causes tissue-specific insulin resistance
35. Cellular mechanisms of insulin resistance in humans
36. Liver pathology and the metabolic syndrome X in severe obesity
37. Insulin resistance: Site of the primary defect or how the current and emerging therapies work
38. Leptin, obesity, and liver disease
39. A resistance movement in NASH
40. Selective deletion of leptin receptor in neurons leads to obesity
41. Effects of the obese gene product on body weight regulation in ob/ob mice
42. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy
43. Animal models of steatosis
44. Serum leptin levels in patients with nonalcoholic steatohepatitis
45. Injury produced by free fatty acids to lysosonies and mitochondria in cultured heart muscle and endothelial cells
46. Effects of fatty acids and ketone bodies on cytochromes p4502B,4A,2E1 expression in primary cultured rat hepatocytes
47. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis
48. Phenotypic abnormalities in macrophages from leptin deficient, obese mice
49. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation
50. Mitochondrial adaptations to obesity-related oxidant stress
51. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion
52. Cytokines in alcoholic and nonalcoholic steatohepatitis
53. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities
54. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis-a pilot study
55. Role of oxidative stress generated from the mitochondrial electron transport chain and mitochondrial glutathione status in loss of mitochondrial function and activation of transcription factor nuclear factor-κ: Studies with isolated mitochondria and rat hepatocytes
56. Chemistry and biochemistry of 4- hydroxynonenal, malonaldehyde and related aldehydes
57. Chemotactic activity of hydroxy-alkenals on rat neutrophils
58. Cytokines and alcoholic liver disease
59. The OB protein (leptin) pathway-a link between adipose tissue mass and central neural networks
60. Tumor necrosis factor in alcohol enhanced endotoxin liver injury
61. Obesity increases sensitivity to endotoxin liver injury: Implications for pathogenesis of steatohepatitis
62. Increased gastrointestinal ethanol production in obese mice: Implications for fatty liver disease pathogenesis
63. Obesity and female gender increase breath ethanol concentration: Potential implications for the pathogenesis of nonalcoholic steatohepatitis
64. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxemia and tumor necrosis factor alpha in the pathogenesis of nonalcoholic steatohepatitis
65. Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of IKKbeta
66. Function and activation of NF - In the immune system
67. Nonalcoholic steatohepatitis
68. Obesity increases sensitivity to endotoxin liver injury: Implications for pathogenesis of steatohepatitis
69. Metformin reverses nonalcoholic fatty liver disease in obese, leptin deficient mice
70. Leptin regulates proinflammatory immune responses
71. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression
72. Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: Role of tumor necrosis factor alpha and IL-18
73. Altered hepatic lymphocyte subpopulations in obesity-related fatty livers
74. Liver regeneration
75. Failure of regeneration of the steatotic rat liver: Disruption at two different levels in the regenerative pathway
76. Disrupted signaling and inhibited regeneration in obese mice with fatty livers: Implications for nonalcoholic fatty liver disease pathophysiology
77. Requirement of JNK for stress-induced activation of cytochrome c-mediated death pathway
78. The predictive value of donor liver biopsy on the development of primary nonfunction after orthotopic liver transplantation
79. Cathepsin B contributes to TNF-alpha mediated hepatocyte apoptosis hy promoting mitochondrial release of cytochrome c
80. Fatty liver vulnerability to endotoxin-induced damage despite NF-κB induction and inhibited caspase 3 acitivation
81. Tumor necrosis factor-alpha stimulates the maturation of sterol regulatory binding protein-1 in human hepatocytes through the action of neutral spingomyelinase
82. Prolonged activation of jun and collagenase genes by tumor necrosis factor-alpha
83. LAP (NF-IL6) transactivates the collagen alpha 1 (I) gene from a 5' regulatory region
84. Identification of mediators stimulating proliferation and matrix synthesis of rat pancreatic stellate cells
85. Agonist-specific regulation of monocyte chemoattractant protein-1 expression by cyclooxygenase metabolites in hepatic stellate cells
86. Stress-activated protein kinases in the activation of rat hepatic stellate cells in culture
87. Quantitative estimation of attenuation in ultrasound video images: Correlation with histology in diffuse liver disease
88. Dual-energy CT in the diagnosis and quantification of fatty liver: Limited clinical value in comparison to ultrasound scan and single energy CT, with special reference to iron overload
89. Noninvasive in vivo quantitative assessment of fat content in human liver
90. Measurement of intracellular triglyceride stores by spectroscopy and validation in vivo
91. Nonalcoholic steatohepatitis in obesity: A reversible condition
92. Non-alcoholic steatohepatitis: Association with obesity and insulin resistance, and influence of weight loss
93. Hepatic effects of dietary weight loss in morbidly obese subjects
94. Adipose tissue is required for the anti-diabetic, but not for the hypolipidemic, effect of thiazolidinediones
95. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis
96. Metformin in non-alcoholic steatohepatitis
97. Dual effect of metformin in cultured rat hepatocytes: Potentiation of insulin action and prevention of insulin induced resistance
98. Metformin reverses fatty liver disease in obese, leptin-deficient mice
99. Pioglitazone and metformin reverse insulin resistance induced by tumor necrosis factor alpha in liver cells
100. Ursodeoxycholic acid or clofibrate in the treatment of nonalcoholic steatohepatitis.: A pilot study
101. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis
102. Effect of simsastatin on inhibition of hydroxy-methylglutaryl coenzyme a reductase on the growth of human ito cells
103. Atorvastatin for the treatment of NASH
104. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane pertubation
105. Effect of ursodeoxycholic acid plus diet in patients with nonalcoholic steatohepatitis
106. Alpha-tocopherol supplementation decreases production of superoxide and cytokines by leukocytes ex vivo in both normolipidemic and hypertriglyceridemic individuals
107. Vitamin E dietary supplementation inhibits tissue growth factor beta gene expression in the rat liver
108. A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C
109. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study
110. Plasma transforming growth factor - Level and efficacy of - Tocopherol in patients with nonalcoholic steatohepatitis: A pilot study
111. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: Results of a pilot study
112. Effect of phlebotomy on serum ALT levels in patients with non-alcoholic steatohepatitis and stainable hepatic iron